| 2025 | 2024 | 2023 | 2022 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 305,2 k € | +24.9% | 244,4 k € | -22.3% | 314,6 k € | -50.4% | 634,9 k € | +113.9% | 296,8 k € | +25.6% | 236,3 k € | +10.1% | 214,6 k € | -7.3% | 231,4 k € | +9.4% | 211,6 k € | +16.5% | 181,7 k € | -34.1% | 275,7 k € | -22.1% | 353,9 k € | +16.6% | 303,6 k € | -16.5% | 363,5 k € | +31.1% | 277,2 k € | +2.0% | 271,8 k € | +3066.6% | 8,6 k € | |
| EBITDA | 297,7 k € | +25.3% | 237,5 k € | -22.3% | 305,7 k € | -51.3% | 627,3 k € | +103.3% | 308,5 k € | +47.4% | 209,2 k € | +12.5% | 185,9 k € | -17.8% | 226,2 k € | +11.3% | 203,2 k € | +13.6% | 178,8 k € | -33.9% | 270,5 k € | -25.5% | 362,9 k € | +28.9% | 281,5 k € | -20.7% | 355,1 k € | +57.4% | 225,6 k € | -16.3% | 269,4 k € | +3213.8% | 8,1 k € | |
| Operating profit | 218,5 k € | +15.8% | 188,8 k € | -26.7% | 257,6 k € | -56.2% | 588,0 k € | +120.0% | 267,2 k € | +58.5% | 168,6 k € | +18.0% | 142,9 k € | -10.8% | 160,2 k € | +37.1% | 116,9 k € | +33.5% | 87,5 k € | -55.8% | 198,3 k € | -26.7% | 270,5 k € | +42.1% | 190,4 k € | -38.3% | 308,4 k € | +71.1% | 180,2 k € | -14.7% | 211,4 k € | +311.8% | -99,8 k € | |
| Profit/loss | 174,9 k € | +28.5% | 136,1 k € | -25.0% | 181,5 k € | -55.1% | 404,2 k € | +138.7% | 169,4 k € | +71.2% | 99,0 k € | +12.5% | 88,0 k € | -11.3% | 99,2 k € | +104.1% | 48,6 k € | -8.4% | 53,0 k € | +5.4% | 50,3 k € | -70.5% | 170,4 k € | +62.4% | 104,9 k € | -23.7% | 137,4 k € | -26.8% | 187,8 k € | +14.2% | 164,5 k € | +264.1% | -100,2 k € | |
| Equity | 1,8 M € | +7.3% | 1,7 M € | +2.2% | 1,7 M € | +12.2% | 1,5 M € | +92.4% | 776,1 k € | +27.9% | 606,7 k € | +19.5% | 507,7 k € | +21.0% | 419,8 k € | +30.9% | 320,6 k € | +17.9% | 272,0 k € | -9.1% | 299,3 k € | +20.2% | 249,0 k € | +216.5% | 78,7 k € | -79.5% | 383,0 k € | +56.0% | 245,6 k € | +324.8% | 57,8 k € | +170.8% | -81,6 k € | |
| Total assets | 2,0 M € | +6.5% | 1,8 M € | +0.7% | 1,8 M € | +0.0% | 1,8 M € | +43.1% | 1,3 M € | -2.5% | 1,3 M € | +15.0% | 1,1 M € | -16.4% | 1,4 M € | +0.4% | 1,4 M € | -0.1% | 1,4 M € | +12.3% | 1,2 M € | +0.6% | 1,2 M € | -18.2% | 1,5 M € | +12.3% | 1,3 M € | +20.1% | 1,1 M € | +24.9% | 869,3 k € | +35.0% | 643,8 k € | |
| Cash | 191,0 k € | -74.1% | 738,4 k € | -33.6% | 1,1 M € | +16.2% | 956,1 k € | +94.6% | 491,4 k € | +4.3% | 471,2 k € | +93.2% | 243,9 k € | -47.7% | 466,5 k € | +1.8% | 458,4 k € | -8.1% | 498,8 k € | +14.7% | 435,0 k € | -5.1% | 458,2 k € | -42.9% | 802,3 k € | +0.3% | 800,1 k € | +43.9% | 555,8 k € | +90.7% | 291,5 k € | +407.8% | 57,4 k € | |
| Debts | 58,0 k € | -10.0% | 64,4 k € | -27.7% | 89,1 k € | -67.0% | 270,0 k € | -35.2% | 416,5 k € | -20.2% | 521,9 k € | -6.2% | 556,6 k € | -34.2% | 846,1 k € | -10.3% | 942,8 k € | -5.4% | 997,0 k € | +27.6% | 781,4 k € | -7.6% | 845,7 k € | -33.5% | 1,3 M € | +55.5% | 817,7 k € | +8.6% | 752,6 k € | -6.4% | 803,8 k € | +10.8% | 725,5 k € | |
| Staff | 0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||
Private limited company · Ronse · incorporated on 25/10/2006 · 0,0 ETP
Private limited company profitable and well capitalised. Cash position declining (-74.1%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Dr.T.Braeckevelt – klinische biologie is a Private limited company incorporated in 2006. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Ronse.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette